Thesis TrackerLoading companies…
All companies
Loading…
Thesis TrackerThesis TrackerLoading…
4DMedical (ASX:4DX), a lung imaging technology company, has gained momentum with major US hospital deployments. In June 2026, Medallion Financial rated 4DMedical a buy, acknowledging it is very expensive but noting consistently good news flow and a large number of contract wins. Perennial highlighted that Mayo Clinic, consistently ranked the top hospital in the US, agreed to deploy its technology, and NorthStar noted strong share price performance on clinical and commercial updates. ELM pointed to FDA clearance for its CT:VQ ventilation-perfusion imaging, while Ellerston reported a 28% fall after ASX 200 index inclusion. 4DMedical operates in the Healthcare sector within the Health Care Technology industry, and Thesis Tracker has captured 6 comments from 5 fund managers, including Medallion, Perennial, NorthStar, ELM and Ellerston. Founded in 2012 by Andreas Fouras and headquartered in Melbourne, 4DMedical commercialises its XV Technology platform, which uses existing X-ray and CT scans to produce detailed lung ventilation imaging.
Company figures as of 15 Oct 2026. For information only.
Fund managers including ELM Responsible Investments have invested in 4DMedical Ltd (ASX:4DX).
Managers highlight FDA clearance for CT:VQ, deployment at Mayo Clinic and other major US hospitals, and a steady stream of contract wins, according to Medallion, Perennial, ELM and NorthStar.
Medallion acknowledges 4DMedical is very expensive, and Ellerston notes a 28% fall after a run-up into ASX 200 inclusion, highlighting volatility.
4DMedical Ltd. is an Australian medical technology company founded in 2012 by Andreas Fouras. Headquartered in Carlton, the company commercializes the XV Technology platform, a four-dimensional lung imaging solution. 4DMedical develops a pipeline of diagnostic tools designed to assist physicians in managing lung disease. Key products include XV ventilation analysis, ventilation perfusion, contrast-free pulmonary angiography, small animal ventilators, and preclinical scanners. These proprietary technologies provide detailed functional lung imaging to improve clinical decision-making and patient outcomes.
General information only. Thesis Tracker reports what named fund managers have published about ASX companies. It does not take into account your objectives, financial situation or needs, and is not financial product advice or a recommendation to buy, sell or hold any security.
11,356 comments from 164 managers on 761 companies, snapshot 15 Oct 2026.